NovaBay Pharmaceuticals, Inc. (NBY) Expected to Post Quarterly Sales of $4.73 Million

Share on StockTwits

Brokerages predict that NovaBay Pharmaceuticals, Inc. (NASDAQ:NBY) will report sales of $4.73 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for NovaBay Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.96 million and the highest estimate coming in at $5.50 million. NovaBay Pharmaceuticals reported sales of $6.32 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 25.2%. The business is scheduled to issue its next earnings report on Tuesday, March 19th.

According to Zacks, analysts expect that NovaBay Pharmaceuticals will report full year sales of $0.00 for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will report sales of $16.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals (NASDAQ:NBY) last announced its earnings results on Wednesday, November 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $4.09 million.

Shares of NASDAQ:NBY traded up $0.03 during midday trading on Wednesday, reaching $1.05. 3,279 shares of the company’s stock traded hands, compared to its average volume of 10,063. NovaBay Pharmaceuticals has a 1 year low of $0.71 and a 1 year high of $4.00.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.

Recommended Story: What is a stock buyback?

Get a free copy of the Zacks research report on NovaBay Pharmaceuticals (NBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Anticipate Cantel Medical Corp.  to Announce $0.62 Earnings Per Share
Brokerages Anticipate Cantel Medical Corp. to Announce $0.62 Earnings Per Share
CenterPoint Energy  Reaches New 12-Month High at $29.72
CenterPoint Energy Reaches New 12-Month High at $29.72
Carvana  Shares Gap Down to $35.50
Carvana Shares Gap Down to $35.50
Insider Selling: Tech Data Corp  VP Sells 592 Shares of Stock
Insider Selling: Tech Data Corp VP Sells 592 Shares of Stock
Arbutus Biopharma Corp  Expected to Announce Earnings of -$0.39 Per Share
Arbutus Biopharma Corp Expected to Announce Earnings of -$0.39 Per Share
Nicolet Bankshares  Issues  Earnings Results
Nicolet Bankshares Issues Earnings Results


Leave a Reply

© 2006-2019 Ticker Report